Literature DB >> 17157790

Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo.

Ingo Ringshausen1, Clodagh C O'Shea, Andrew J Finch, Lamorna Brown Swigart, Gerard I Evan.   

Abstract

There is currently much interest in the idea of restoring p53 activity in tumor cells by inhibiting Hdm2/Mdm2. However, it has remained unclear whether this would also activate p53 in normal cells. Using a switchable endogenous p53 mouse model, which allows rapid and reversible toggling of p53 status between wild-type and null states, we show that p53 is spontaneously active in all tested tissues of mdm2-deficient mice, triggering fatal pathologies that include ablation of classically radiosensitive tissues. In apoptosis-resistant tissues, spontaneous unbuffered p53 activity triggers profound inhibition of cell proliferation. Such acute spontaneous p53 activity occurs in the absence of any detectable p53 posttranslational modification, DNA damage, or p19ARF signaling and triggers rapid p53 degradation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17157790     DOI: 10.1016/j.ccr.2006.10.010

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  119 in total

Review 1.  Mouse models of p53 functions.

Authors:  Guillermina Lozano
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

Review 2.  Posttranslational modification of p53: cooperative integrators of function.

Authors:  David W Meek; Carl W Anderson
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10-28       Impact factor: 10.005

3.  IBRDC2, an IBR-type E3 ubiquitin ligase, is a regulatory factor for Bax and apoptosis activation.

Authors:  Giovanni Benard; Albert Neutzner; Guihong Peng; Chunxin Wang; Ferenc Livak; Richard J Youle; Mariusz Karbowski
Journal:  EMBO J       Date:  2010-03-18       Impact factor: 11.598

Review 4.  Making sense of ubiquitin ligases that regulate p53.

Authors:  Abhinav K Jain; Michelle Craig Barton
Journal:  Cancer Biol Ther       Date:  2010-10-01       Impact factor: 4.742

5.  Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.

Authors:  Annette Künkele; Katleen De Preter; Lukas Heukamp; Theresa Thor; Kristian W Pajtler; Wolfgang Hartmann; Michel Mittelbronn; Michael A Grotzer; Hedwig E Deubzer; Frank Speleman; Alexander Schramm; Angelika Eggert; Johannes H Schulte
Journal:  Neuro Oncol       Date:  2012-05-16       Impact factor: 12.300

Review 6.  The p53 orchestra: Mdm2 and Mdmx set the tone.

Authors:  Mark Wade; Yunyuan V Wang; Geoffrey M Wahl
Journal:  Trends Cell Biol       Date:  2010-02-19       Impact factor: 20.808

7.  cIAP2 represses IKKα/β-mediated activation of MDM2 to prevent p53 degradation.

Authors:  Rosanna Lau; Min Ying Niu; M A Christine Pratt
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

Review 8.  Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Authors:  Mark Wade; Geoffrey M Wahl
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

Review 9.  20 years studying p53 functions in genetically engineered mice.

Authors:  Lawrence A Donehower; Guillermina Lozano
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

Review 10.  p53--a Jack of all trades but master of none.

Authors:  Melissa R Junttila; Gerard I Evan
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.